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Abstract  
Cancer is one of the most malignant diseases in the world, accounting for 7.6 million deaths (around 13% of all 
deaths) in 2008 based on WHO reports. Early detection of cancer is vital due to its final control and prevention. 
Despite advances in diagnostic strategies, they have not the required sensitivity and specificity for prognosis. 
During the last decays, one of the most challenges for cancer research is to determine biological basis of this 
malignancy as a characteristic agents for an early-stage cancer. Understanding these agents requires molecular 
level examination of the disease followed by analysis of protein networks and their interactions in cells, signaling 
events among cancer cells, interactions among the cancer cells, and the tumor microenvironment. Proteomics as 
one of the modern areas of biochemistry holds great promise in cancer study. Inasmuch as, proteome reflects the 
real state of a cell, tissue or organism, it is expected to achieve more accurate tumor markers for disease diagn osis 
and therapeutic monitoring. In fact, the utility of this innovative large-scale proteome analyzer has shown 
significant prospective in biomarker discovery, patient monitoring, drug targeting and cell signaling; moreover, 
advances in the field of proteomics will provide new insight into the molecular complexity of the disease process, 
and enable the development of tools to help in treatment as well as in detection and prevention. In this review, 
proteomics approaches in cancer studies have been represented and discussed.  
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1. Introduction 
Cancer is one of the major life threatening 
diseases in 21 century. In 2008, about 7.6 
million deaths (around 13% of all deaths) of 
cancer were reported. The gradual elimination of 
some other fatal diseases, combined with rising 
life expectancy, means that the risks of 
developing cancer are fluctuated slightly. The 
numbers of deaths from cancer worldwide are 
gradually rising, with an estimated 12 million 
deaths in 2030 [1]. Cancer has been a focus of 
biomedical studies for decades. The multigenic 
characteristic of cancer has led to progress in 
understanding of mechanisms of a specific 
disease phenotype [2]. Despite recent advances 
in the diagnosis and treatment of cancer, tumor 
cell progression and metastasis are the main 
cause of morbidity and mortality in cancer 
patients [3]. Most cancers are initially 
recognized either because signs or symptoms 
appear or through screening. Some tumors may 
not have any symptoms at all.  In some certain 
cancers like gallbladder cancer, symptoms often 
do not start until the disease has reached its 
advanced stage. Consequently, more tools that 
are sensitive are required for early detection of 
diseases. Over the last 15 years, powerful 
high-throughput technologies, such as DNA 
microarrays, cDNA subtractions, and serial 
analysis of gene expression (SAGE), have been 
widely applied for identifying novel cancer 
related genes and for classifying cancers at the 
molecular level [4]. The cancer researchers are 
discovered varieties of biomarkers and 
therapeutic targets of different kinds of cancers 
recently. For instance, PSA is an appropriate 
diagnostic biomarker for Prostate cancer; 
furthermore, the most commonly used 
biomarker for ovarian cancer is CA125; 
nevertheless, malignancies are commonly 
detected at severe stages when patients have 
very poor prognosis and few treatment options 
that are mostly due to a high cost and 
time-consuming process in biomarker tracing. 
Thus, development of a better throughout 
analyzer method is a critical requirement for 
early detection, biomarker assay, and 
combination of the various platforms of 
oncoproteome data. Since proteome changes 
dynamically related to the state of an organism, 
it seems that proteomics as a high-throughput 
technique can uncover greater insight in to 
cancer biology rather than classical 
biochemistry, and statically methods such as 
genomics. It  holds great promises for solving 
this matter by identifying biochemical 
evaluations of a disease process [5], and can be 
an accurate technology for cancer curing 
purposes. This high throughout scale provides 
new aspects for protein identification, 
quantization, fractionation, and enrichment to 
delve deeper into the oncoproteome in one 
single experiment. Cell lines, tissues, saliva and 
plasma/serum as the various sources of human 
samples are probed by a plethora of proteomics 
tools to discover novel biomarkers and elucidate 
mechanisms of tumor genesis [6]. Proteomics 
technologies and strategies are applied to 
determine therapy efficacy, identify novel drug 
targets, and ultimately develop personalized 
medicine for human malignancy [7, 8]. However, 
some limitations such as technical errors in the 
sensitivity of detecting low abundant 
biomarkers , probable systematic biases in the 
observed data, and biological heterogeneity 
manipulations are required to get improved in 
order to bring out the adequate cancer proteome 
mining [9, 10]. This article underlies the 
proteomics significant roles in cancer early 
detection and prevention from many 
perspectives. 
2. Proteomics techniques and 
cancer 
Proteomics contains two fundamental methods 
for protein characterization; first is proteins 
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separation by the tools such as two-dimensional 
polyacrylamide gel electrophoresis (2D-PAGE) 
that was first introduced by P. H. O'Farrell, and 
the second is usage of  mass spectrometry 
(MS) for protein identification purposes, which 
has greatly improved in accuracy and 
throughput recently [11]. The proteins separate 
according to their physicochemical properties 
and then the desired proteins considering their 
expression or function identify by MS 
techniques [12, 13]. Furthermore, 
surface-enhanced laser desorption/ionization 
time-of-flight (SELDI-TOF) -MS is the 
backbone for serum or plasma analysis. Other 
methods including isotope-coded affinity tag 
technology, reverse-phase protein arrays, and 
antibody microarrays are emerging as 
alternative proteomic modus [14]. Data output 
from 2D-PAGE as a classical technique in 
proteomics is normally slow and analysis is 
limited to low-throughput means. This 
technology is not a rapid method for screen 
large sample numbers. In spite of these 
considerations, 2D-PAGE is still an efficient 
and common way to study several human 
cancers, both for expression and functional 
purposes. Expression proteomic studies are 
screening for differences in protein patterns 
between tumor and control samples. Many 
biological sources have been explored to 
generate valid comparisons for studying cancer 
proteome including cancer cell lines, human 
tissues and body fluids [15]. 
Overall, proteomics technologies can assist the 
development of cancer studies as follows [16]: 
 Development of molecular detection 
(biomarker discovery) of cancer for 
diagnostic proposes. 
 Proteomics provides a better 
understanding of molecular pathology 
of cancer (cell signaling). 
 Drug targeting, facilitating integration 
of diagnostic and therapeutic aspect of 
cancer (personalized cancer care). 
 Upgrade classification of cancer. 
 Toxiproteomics; that could help in the 
development of safer therapies for 
cancer via identifying toxic effects of 
anticancer drugs at an early stage  
 Patient monitoring  
3. Molecular Detection 
(Prognostic and Biomarker 
Discovery) and Cell Signaling 
A challenge in the treatment of cancer is the 
lack of early diagnostics. Since then, diagnosis 
is vital for prevention before its clinical 
demonstrations and its ultimate control, the 
molecular biology of cancer had been studied 
by different means such as proteomics that may 
make it possible to detect cancer at an early 
stage and arrange the treatment much more 
manageable. Although advances in 
conventional diagnostic strategies such a 
mammography and prostate specific antigen 
(PSA) testing have provided some specific 
improvement in detection of cancer, they still 
did not reach sensitivity and specify that are 
needed detecting early-stage disease. Most of 
the time, cancer is not detected and treated until 
cancer cell have already attack other tissues 
[17].    
Cancer molecular pathway is complex and 
has a range of transcriptional and 
post-translational modified proteins. Besides, 
gene expression may change because of gene 
mutations or changes in environmental 
conditions and life style. Because many genes 
and several environmental factors are involved 
in cancer, mechanism of the development of 
several types of cancers is different. 
Consequently, by identifying these molecular 
pathways and molecular indicators called 
biomarkers, considerable improvement in 
cancer therapy may be achieved [18-20]. Indeed, 
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it is necessary that reproducibility and 
validation of these biomarkers address carefully, 
as their origin and identity. If these efforts are 
made, protein profiling can contribute to the 
better diagnosis of patients and the optimization 
of their treatment [21]. Some common cancer 
biomarkers and their related characteristic 
represent in table1. 
To examining, the molecular changes that 
create these phenotypic and malignant changes, 
proteomic methods are now being used to study 
variations in protein expression, modifications, 
and enzyme activity [22, 23]. In addition to this, 
identifying key proteins and their changed 
regulatory role makes a new insight into the 
evolutionary process of tumor cells disclosing 
new functions and phenotypes [12, 15, 24]. The 
lack of confidence in using a particular single 
protein as a biomarker for a disease has led to 
the development of a panel of proteins as 
biomarkers instead of a single protein for 
certain diseases. It is shown that an increase in 
a combination of four proteins, such as leptin, 
prolactin, osteopontin, and insulin-like growth 
factor II, serves as a good indicator of ovarian 
cancer [25]. Another usage of proteomics is to 
elucidate the molecular mechanisms and 
signaling events that lead to cancer 
development [12].While genomic approaches 
have been used to establish the “blue-prints” of 
p53 signaling and its target genes, proteomics 
has become an essential tool to approve such 
information. Although the data obtained from 
functional genomics may explain more about 
p53 signaling, several other mechanisms 
involved are not gene mediated. In addition, 
information obtained from such study is limited, 
especially when post-transcriptional and 
post-translational modifications occur. The 
level of p53 modifies by many different 
products or proteins, which directly determine 
differential cellular functions and responses. 
Therefore, alliance of genomics and proteomics 
information with respect to one gene is 
important [26]. 
To examining, the molecular changes that 
create these phenotypic and malignant changes, 
proteomic methods are now being used to study 
variations in protein expression, modifications, 
and enzyme activity [22, 23]. In addition to this, 
identifying key proteins and their changed 
regulatory role makes a new insight into the 
evolutionary process of tumor cells disclosing 
new functions and phenotypes [12, 15, 24]. The 
lack of confidence in using a particular single 
protein as a biomarker for a disease has led to 
the development of a panel of proteins as 
biomarkers instead of a single protein for 
certain diseases. It is shown that an increase in 
a combination of four proteins, such as leptin, 
prolactin, osteopontin, and insulin-like growth 
factor II, serves as a good indicator of ovarian 
cancer [25]. Another usage of proteomics is to 
elucidate the molecular mechanisms and 
signaling events that lead to cancer 
development [12].While genomic approaches 
have been used to establish the “blue-prints” of 
p53 signaling and its target genes, proteomics 
has become an essential tool to approve such 
information. Although the data obtained from 
functional genomics may explain more about 
p53 signaling, several other mechanisms 
involved are not gene mediated. In addition, 
information obtained from such study is limited, 
especially when post-transcriptional and 
post-translational modifications occur. The 
level of p53 modifies by many different 
products or proteins, which directly determine 
differential cellular functions and responses. 
Therefore, alliance of genomics and proteomics 
information with respect to one gene is 
important [26].
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Table1 some cancer biomarkers and their related information 
Tumor markers Related cancers Non-cancer-related condition Clinical usage Source 
AFP(Alpha-feto    
protein) [22, 23] 
Liver, germ cell 
cancer of ovaries or 
testes 
Also elevated during pregnancy 
Help diagnose, 
monitor treatment, 
and determine 
recurrence 
Blood 
 
B2M (Beta-2 
microglobulin) [24] 
Multiple myeloma 
and lymphomas 
Present in many other conditions, 
including Crohn's disease and 
hepatitis; often used to determine 
cause of renal failure 
Determine 
prognosis 
Blood 
CA 15-3 (Cancer antigen 
15-3) [25] 
Breast cancer and 
others, including 
lung, ovarian 
Also elevated in benign breast 
conditions; doctor can use CA 15-3 
or CA 27.29 (two different assays 
for same marker) 
Stage disease, 
monitor treatment, 
and determine 
recurrence 
Blood 
CA 19-9 (Cancer antigen 
19-9) [26] 
Pancreatic, 
sometimes 
colorectal and bile 
ducts 
Also elevated in pancreatitis and 
inflammatory bowel disease 
Stage disease, 
monitor treatment, 
and determine 
recurrence 
Blood 
CA-125 (Cancer antigen 
125) [27] 
Ovarian 
Also elevated with endometriosis, 
some other benign diseases and 
conditions; not recommended as a 
general screen 
Help diagnose, 
monitor treatment, 
and determine 
recurrence 
Blood 
Calcitonin [27] 
Thyroid medullary 
carcinoma 
Also elevated in pernicious anemia 
and thyroiditis 
Help diagnose, 
monitor treatment, 
and determine 
recurrence 
Blood 
CEA 
(Carcino-embryonic 
antigen) [28] 
Colorectal, lung, 
breast, thyroid, 
pancreatic, liver, 
cervix, and bladder 
Elevated in other conditions such as 
hepatitis, COPD, colitis, 
pancreatitis, and in cigarette 
smokers 
Monitor treatment 
and determine 
recurrence 
Blood 
Her-2/neu [29] Breast 
Oncogene that is present in multiple 
copies in 20-30% of invasive breast 
cancer 
Determine 
prognosis and guide 
treatment 
Tissue 
PSA (Prostate specific 
antigen), total and free 
[30] 
Prostate  
Elevated in benign prostatic 
hyperplasia, prostatitis and with age 
Screen for and help 
diagnose, monitor 
treatment, and 
determine 
recurrence 
Blood 
Thyroglobulin [31] Thyroid  
Used after thyroid is removed to 
evaluate treatment 
Determine 
recurrence 
Blood 
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4. Personalized Therapy via 
Molecular Targeting Strategies 
Effective ways of treating cancer has been a great focus 
of biomedical investigation for decades. Cancer affects 
every patient and family in a different way. The most 
therapeutic challenges is to design a specific drug for 
each individual [2]. As proteins are the cause of 
diseases such as cancer in a way that, contribute to 
tumor formation, progression and metastasis, so 
knowledge of these individual molecules and 
deciphering signaling pathways can assist identify and 
characterize proteins involved in the disease and 
suggest combinatorial therapeutic strategies such as 
designing smart drugs [16]. One of the good examples 
of these molecules is PTK (Protein tyrosine Kinases) 
and other kinases that represent the feature of many 
cancers. These molecules placed in key positions in the 
signaling network; which are attractive targets for drug 
development such as inhibitors [27]. Drug targeting is a 
new developed way of treatment achieved by new 
molecular detection strategies such as proteomics. Thus, 
proteomics as a noteworthy technology can facilitate 
this way by the molecular highlighted methods [2, 28]. 
These methods aid to the identification of protein 
biomarkers, their modification, and altered metabolic 
pathways by comparison of the proteomes of normal 
cell and cell from a patient that leads to drug designing. 
In addition to this, bioinformatics is used for drug 
designing and in their final selection as a drug candidate, 
which is then used for biochemical and toxicological 
tests in animal model system and then in human before 
its approval by the FDA [29, 30]. Furthermore, 
knowledge of metabolic pathways and that of proteins 
interactions associated with bioinformatics tools 
facilitate the development of drugs in a cost-effective 
manner. In the future, high throughput screening (HTS) 
methods in a cost-effective manner will provide the 
interaction of possible chemicals as drugs with the 
target proteins rapidly. The use of combinatorial 
chemistry and the library of chemicals available on the 
database [31, 32] will aid this technique. In addition, as 
drug development is an expensive performance [32], 
proteomics is expected to decrease the expenses by 
increasing the number of target proteins used for the 
drug designed. Therefore, proteomics strategies make it 
feasible to translate basic science discoveries into the 
clinical application of personalized medicine and 
remedies [2]. 
5. Role of Proteomics in Cancer 
Classification 
Recent reports signify that global proteomic approach 
may procreate the WHO disease classification including 
human cancers [33].Tumor classification is currently 
based on the idea of cell of origin. It is necessary that 
cancer classification affected by functional attribute of 
cancer cells. Inherently, all organs can produce various 
cancer forms as multiple cell types exist in these organs 
[34, 35]. The last two decades have witnessed the rise in 
molecular profiling which has already helped in better 
understanding of tumor development and identification 
cancer molecular classification. Current molecular 
classification systems are still dependent on 
morphologic variables. These classifications schemes 
use cell of origin as seen by light and electron 
microscopy [36, 37]. What is more, cancer classification 
schemes always reserve a group as unclassifiable that 
the subtypes are generated under the banner of a single, 
specific cell type of origin concept [38]. Therefore, the 
question is aroused that what model can serve 
unclassifiable cancers in a specific location. The 
integrated model of cancer classification presented here 
incorporates all morphology, cancer stem cell 
contributions, genetic, and functional attributes of 
cancer. Integrated cancer classification models could 
eliminate the unclassifiable cancers as used in current 
classifications. 
Proteomics is one of the choices for classification of 
tumor origin and states, based on their molecular source 
[29, 30]. These molecules such as tyrosine kinases 
(PTKs) and their substrates are emerging as appropriate 
therapeutic targets and potential biomarkers for 
molecular classifications. The biological variability 
among patient samples as well as the huge dynamic 
range of biomarker concentrations is currently the major 
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challenges facing efforts to lessen diagnostic patterns 
that are unique to specific disease states. 
High-throughput profiling of the protein content of 
complex samples is detectable by recent advances in MS 
technology. For cancer classification, the protein 
samples from cancer patients relative to normal or from 
different cancer stages analyze through MS appliance 
and the MS patterns uses to build a diagnostic classifier. 
For example, lung cancers are traditionally classified 
into various subtypes on a histological basis. 
Adenocarcinoma and other histologists follow 
squamous lung cancer, the most common histological 
subtype. These various subtypes were classified based 
on 2D-PAGE [36] and MS profiles [39]. Future cancer 
treatments may be advanced by using an integrated 
model of cancer classification such as proteomics 
methods [40]. 
6. Toxicoproteomics 
Toxicoproteomics is a new scientific method that 
combines proteomic technologies with bioinformatics. 
The emerging field of toxicoproteomics has been 
developed by quantitative and qualitative proteomics 
strategies and its increasing applications in toxicology 
study [41, 42]. This method seeks to identify important 
proteins and pathways in biological systems that are 
affected by toxicants, adverse chemical and 
environmental exposures using global protein 
expression technologies in mapping serum, plasma and 
other biofluid proteomes, and in parallel proteomic and 
transcriptomic studies toward understanding 
pathophysiology, and biomarker discovery of diseases 
including cancer [43-45]. Cancer is spread through any 
source of pollution namely through water pollution, air 
pollution and land pollution. A number of chemicals 
contaminations present in air, water, food and 
workplace are capable of inducing cancer. Many studies 
have discovered the link of various types of 
environmental pollution with the development of cancer. 
Although many of them have been classified as 
carcinogens according to United States of 
Environmental Protection Agency and International 
Agency for research on cancer; the understanding of 
their mechanism is still insufficient, and remained to 
identify [46]. In contrast to toxicogenomics, a discipline 
that determines genetic susceptibility of a particular 
individual following exposure to a carcinogenetic agent, 
toxicoproteomics allow the monitoring of the body’s 
response to a specific toxicant. This advances supplies a 
means to identify and characterize mechanisms of 
action of toxicants in carcinogenesis. The current 
regulatory toxicological approach usually includes 
investigation of carcinogenicity, in generally lengthy (2 
years) studies in rodents. This is especially true for 
detection of early protein biomarker signatures that 
precede neoplastic appearance [46]. Various examples 
exhibit the potential of proteomic approaches to reduce 
time and expense of traditional carcinogenicity testing. 
For instance, the liver carcinogen N-nitrosomorpholine 
(NNM) investigated in rats to identify potential early 
protein biomarker signatures indicative of the 
carcinogenic processes. Analysis was performed 18 
weeks following treatment revealed significant up 
regulation of stress proteins, including caspase-8 
precursor, vimentin, and Rho GDP dissociation inhibitor. 
Interestingly, the findings indicate that this treatment 
deregulates annexin A5 and fructose-1, 
6-bisphosphatase.  In addition, determining toxic 
effects of anticancer drugs at an early stage is useful for 
developing safer cancer therapies [47]. This finding 
may indicate their potential use as predictive 
biomarkers for early liver carcinogenicity [48]. 
7. Patient Monitoring  
It is essential to know whether patients with malignant 
tumors are benefiting from the administered therapy or 
not. So, following initiation of treatment, serum probes 
can be observe for responding to therapy, screening and 
prediction of the therapeutic efficacy, as well as 
determining whether the tumor has developed resistance 
mechanisms that may need modification of treatment, 
that is called responder profiling. Multilabel detection 
coupled with high capture molecule density in 
immunosensors and arrays seems to be proficient of 
detecting a wide range of protein concentrations with 
sensitivity ranging into the sub pg mL
−1
 level. 
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Multilabel arrays can be designed to detect both high 
and ultralow abundance proteins in the same sample. 
Although, only a few of the newer ultrasensitive 
methods have been evaluated with real patient samples, 
which is key to launch clinical sensitivity and 
selectivity [49]. Proteomic technologies, such as serum 
protein pattern profiling, combined with protein 
microarray technologies, constitute a new paradigm for 
detecting disease and monitoring disease response to 
therapy [50]. Protein biomarkers such as CEA, CA 153, 
AFP,PTKs and PSA are useful  for therapy monitoring, 
and it is reasonable that these biomarkers will be 
complemented by others in the future [6, 51]. As 
mentioned above, one of the best examples for 
monitoring treatment in patients with ovarian cancer is 
CA 125 [52].Response according to CA 125 occurred if 
there was either a 50% or a 75% reduction in CA 125 
levels [53]. Following healing excision for primary 
cancer, it is now a common practice to follow-up 
patients at regular intervals. The main goal of this 
surveillance is to detect recurrent/metastatic disease at 
an early stage, the supposition being that the early 
detection of disease progression followed by the 
beginning of therapy, increase patient outcome 
compared to initiating therapy when the patient is 
symptomatic [44]. Finally, proteomics and genomics 
together are necessary for cancer patient management 
through the design and tracking of individualized 
therapy, and can possibly revolutionize cancer 
monitoring. 
8. Proteomics Approach in 
Different Types of Cancer 
8.1. Lung Cancer 
Lung cancer is the most frequent type of cancer in the 
world [54]. There is a low overall 5-year survival rate, 
ranging from 10 % - 14 %. Early studies on lung cancer 
proteomics first published in the beginning of 1990s. 
These initial studies focused on the relationship 
between histopathological characteristics and 2D-PAGE 
reproducibility [55, 56]. A few years later, the first 
differentially expressed proteins in lung cancer were 
determined in small cell lung cancer (SCLC), including 
tubulin, heatshock proteins 73 and 90, lamin B, and 
proliferating cell nuclear antigen (PCNA). This study 
indicates for the first time that 2D-PAGE merge with 
protein identification was a noble approach to identify 
biomarkers in cancer [57]. After that, with 
improvements in MS technology, it was possible to 
identify about 20 potential biomarkers in lung cancer 
tissue [58]. 
 A SELDI study in early stages in lung cancer and 
premalignant bronchial lesions analyzed LCM 
specimens of normal lung, atypical adenomatous 
hyperplasia and malignant tumors taken from patients 
participating in a screening program. Protein profiles 
were generated in each epithelial cell type and found to 
be in a great number reproducible in classifying 
populations at high risk for lung cancer [59]. Another 
study compared serum samples from lung cancer and 
healthy controls. Five protein peaks in a blinded test 
achieved a sensitivity of 87%, a specificity of 80%, and 
a positive predictive value of 92%. Sensitivity was even 
considerably better (91%) for detection of nonsmall cell 
lung cancers (NSCLC) [60]. Study of circulating 
autoantibodies in lung cancer patients  was uncovered 
antibodies against annexins I and II, recoverin, protein 
gene product 9.5, and enolase [61]. Another 
comparative study between normal and non-small-cell 
lung cancer patients with the usage of Label-free 
quantitative liquid chromatography tandem mass 
spectrometry (1D-LC/MS/MS) shows that, 62 proteins 
were differentially expressed between non-small-cell 
lung cancer patients and normal controls which made it 
possible to distinguish non-small-cell lung cancer from 
the normal controls [62]. 
A combination of two dimensional gel 
electrophoresis LC-tandem mass spectrometry of A549 
cells before and after green tea extract (GTE) exposure 
identified 14 protein spots that changed in expression 
(≥2 fold) after GTE treatment. These proteins are 
involved in calcium binding, cytoskeleton and motility, 
metabolism, detoxification or gene regulation. The 
result of the study demonstrates that GTE alters the 
levels of many proteins involved in growth, motility 
and apoptosis of A549 cells and their identification may 
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show the multiple anti-tumor activities of GTE [63]. 
Recent proteomic results have elucidated new aspects 
of derivation and validation a signature from the 
proteomic analysis of bronchial lesions that could 
predict the diagnosis of lung cancer. The possibility of 
having lung cancer based on the proteomic analysis of 
the bronchial specimens was characterized by an area 
under the receiver operating characteristic curve of 0.77 
(95% CI 0.66–0.88) in this validation cohort. These 
results indicated that proteomic analysis of 
endobronchial lesions might facilitate the diagnosis of 
lung cancer and the monitoring of high-risk individuals 
for lung cancer in surveillance and chemoprevention 
trials [64]. 
8.2. Breast Cancer 
Several proteomic technologies have been applied in 
different studies to discover biomarkers and molecular 
mechanisms associated with breast carcinoma, the most 
frequent cancer-related death in women which is 
accounted for 1.15million new cases and 410,000 
deaths in 2002 [65-68]. For example, 2D-PAGE 
combined with MS analyzed changes in the proteome 
of infiltrating ductal carcinoma compared to normal 
breast tissue. Twenty-five differentially expressed 
proteins were identified comprising cell defense 
proteins, enzymes involved in glycolytic energy 
metabolism and homeostasis, protein folding and 
structural proteins, and proteins involved in 
cytoskeleton and cell motility. Further proteins were 
also mapped to establish a 2D-PAGE reference map of 
human breast cancer [69]. Another proteomic study, 
combining 2D-PAGE, MS, immunoblotting, and 
antibody arrays analyzed the proteome from adipose 
cells and interstitial fluid collected from mastectomy 
specimens of high-risk breast cancer patients to find 
factors present in the tumor microenvironment and 
responsible for tumor growth and development. A total 
of 359 unique proteins were diagnosed, including 
plentiful signaling molecules, hormones, cytokines, and 
growth factors involved in a variety of biological 
processes such as signal transduction and cell 
communication, energy metabolism, protein 
metabolism, cell growth and/or maintenance, immune 
response, transport, regulation of nucleobase, 
nucleoside, and nucleic acid metabolism, and apoptosis 
[61]. This proteomics study provided a unique 
phenotypic overview of tumor microenvironment in 
human epithelial cancer. Using SELDI-TOF, it was 
shown that combined measurement of serum 
complement component C3a (desArg) and a 
C-terminal-truncated form of C3a (desArg) 
considerably differentiates breast cancer patients from 
noncancerous controls [70].  
In a confirmatory study on independent samples, C3a 
(desArg) appeared to lack specificity between patients 
with benign diseases [71]. This work could be partially 
validated in an independent prospective study where 
some peaks of interest could be detected, but the 
sensitivity for cancer detection was only between 33 
and 45% [72]. SELDI-TOF was also applied to the 
analysis of breast ductal lavage and was start up to 
improve the potential of cytology [73]. Proteomic 
researches could also discredit putative data achieved 
with transcriptomic technologies; for instance, applying 
a proteomic approach complemented by 
immunohistochemical analysis showed that levels of 
expression of 14-3-3 sigma were alike with matched 
malignant and nonmalignant breast epithelial tissue. In 
addition to its biological features, the methodological 
relevance of this finding should be considered, since 
transcriptional expression of the sigma isoform of 
14-3-3 is frequently impaired in human cancers, 
including breast, which has led to the suggestion that 
this protein might be involved in the neoplastic 
transformation of breast epithelial cells [74]. Another 
research indicates that, breast tumors lacking the 
estrogen receptor-α (ER-α) have increased incidence of 
resistance to therapy and poorer clinical prognosis. 
Comparative proteomic analysis of pooled tumors that 
were chosen base on being either ER-α-positive or 
ER-α-negative unexpectedly revealed differentially 
abundant [75] phosphorylated isoforms of the 
cytochrome b5-domain protein and progesterone 
receptor membrane component (PGRMC)1 [76] among 
these tumors. Two of three spots of PGRMC1 were 
more abundant in estrogen receptor negative tumors. 
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Thus, PGRMC1 phosphorylation may be play a role in 
the clinical differences that uphold breast tumors of 
differing ER status. 
More studies by two-dimensional DIGE and mass 
spectrometry have resulted in the identification of 
ligand dependent multiprotein complex such as β-actin, 
myosins, and several proteins involved in actin filament 
organization and dynamics [77]. 
8.3. Colon Cancer 
CRC (colorectal Cancer) is the second universal life 
threatening cancer in the world [78]. About 10 years 
ago, the first 2D-PAGE map of purified colorectal 
epithelial cells was published [79, 80]. At that time, it 
was possible to identify about 50 polypeptides, most of 
them by N-terminal sequencing since MS technology 
was only developing. In the meantime, expression 
proteomic researches were performed with cell lines, 
whole tissue biopsies, and purified epithelial cells of 
colorectal origin [81]. It was possible to synthesize 
translational studies results achieved in CRC in a 
quasimeta analysis out of 408 differentially expressed 
proteins, which  83% were found to be differentially 
expressed only in a single study, 16 proteins in 3 studies, 
10 in 4 studies, 3 in 5 studies, and only a single protein 
in 8 studies. Confirmation at proteome level using 
large-scale transcriptomic studies was possible in only 
25%. This proportion was higher (67%) for validating 
proteome results using transcriptomic methods. Clearly, 
reproducibility and overlap between published gene 
expression results at proteome and transcriptome level 
are low in human CRC. Essentially, the whole number 
of patients involved in the proteomic researches was 
only 11, a surprisingly low figure. Using SELDI 
technology, defensin isoforms were found to be 
elevated in serum from colon cancer patients and in 
protein extracts from CRC [82]. This result was 
approved by expression determinations of microarray 
data achieved from 283 tumors and normal tissues 
followed by serum analysis of colon cancer patients and 
controls by ELISA. This study profit a diagnostic 
sensitivity of 70% and specificity of 83% for α-defensin 
in colon cancer [83]. Despite the fact that, these figures 
appear too low for developing a screening test, this 
result is an appealing proof of concept for integrating 
tissue transcriptomic data with serum protein analysis as 
a means to discover serum biomarkers.  
Another study in CRC tissue combined 2D-PAGE with 
SELDI-MS. This study clarified that PACAP protein, 
hnRNP A1, flavin reductase, calgizzarin, NDKB 
(NM23H2), cyclophilin A, and smooth muscle protein 
22 showed considerably different levels. Subsequent 
immunohistochemical analysis of tissue distribution and 
subcellular localization of some of the differentially 
expressed proteins demonstrated alterations in 
subcellular protein distribution [84]. In another studies, 
a comparative proteomic study reveals that bacterial 
CpG motifs induce tumor cell autophagy in Vitro and in 
Vivo. These studies followed by two-dimensional gel 
electrophoresis and mass spectrometry identified 
numerous proteins modulated by bacterial CpG motifs, 
which many are related to autophagy including 
potential autophagic substrates. Besides, it was 
observed that, an increased glyceraldehyde-3-phosphate 
dehydrogenase expression, which has been shown to be 
sufficient to activate an autophagic process. Therefore, 
this study brings new insights on the effect of bacterial 
CpG motifs in tumor cells and may be useful for cancer 
therapy and more generally for gene therapy purposes 
in TLR9-positive tissues [84]. 
Recent proteomics based on one-dimensional gel 
electrophoresis coupled to nanoliquid chromatography 
tandem showed proteome differences between colon 
cancer stem cells and differentiated tumor cells. Out of a 
total data set of 3048 recognized proteins, 32 proteins were at 
least two fold up regulated in the colon cancer stem cells 
comparing with the differentiated cells. Pathway analysis 
showed that “cell death” regulation is remarkably different 
among the two cell types. Interestingly, one of the 
top-up-regulated proteins was BIRC6, which belongs to the 
class of inhibitor of apoptosis proteins. BIRC6 is an important 
mediator of cancer stem cell resistance against cisplatin and 
oxaliplatin. Targeting BIRC6, or other Inhibitors of apoptosis 
proteins, may help exterminate colon cancer stem cells. This 
study reveals that differentiation of colon cancer stem cells is 
accompanied by altered regulation of cell death pathways 
[84]. 
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8.4. Gastric Cancer 
Gastric cancer refers to cancer arising from any part of 
the stomach. It is the fourth most common malignant 
cancer worldwide [85, 86]. More than 990 000 cases 
come about yearly based on 2008 reports [85, 87]. 
Proteomics as a High-throughput molecular 
determination method represents promising in this field. 
The first proteomics analysis of gastric cancer was in 
2001 which was about characterization of the differential 
protein expression associated with thermo resistance in 
human gastric carcinoma cell lines [88, 89]. Primary 
biomarker screening in gastric cancer performed using 
2D-PAGE on purified gastric epithelial cells from 
gastrectomy specimens. In this study, 191 deferentially 
expressed proteins were identified by mass 
spectrometry. Overexpression of cathepsin B was 
detected in most cancer tissue samples. Elevated serum 
levels of cathepsin B were associated with a reduced 
survival rate, enabling the classification of some gastric 
cancer patients into a subgroup that should undergo 
aggressive therapy. Later on, other studies were 
performed based on biomarker discoveries. In one of 
these studies, NSP3, transgelin, prohibitin, heat shock 
protein (hsp) 27, and protein disulfide isomerase A3 
proteins were indicated as over-expressed molecules in 
tumor tissue samples, when compared to normal tissue 
samples [90]. In another research, eight proteins, 
including 14-3-3 zeta, calcyclin, keratin, apolipoprotein 
A-1 precursor, proteasome activator complex subunit, 
nucleoside diphosphate kinase, nicotinamide 
N-methyltransferase, and pyridoxal kinase were 
detected as possible biomarkers [91]. Two other 
promising biomarker studies are characterization of 
pepsinogen C as a potential biomarker for gastric cancer using 
a histo-proteomic. For this aim, 74 cryostat sections of 
central gastric tumor, tumor margin, and normal gastric 
epithelium using protein chip arrays and SELDI-TOF 
MS studied. One peak was significantly down regulated 
in tumor tissue (P = 1.43 × 10
-6
) and identified as 
pepsinogen C. This signal was further characterized by 
immunohistochemistry [91, 92]. Last example is 
identification of IPO-38 as a novel serum biomarker both for 
diagnosis and prediction prognosis of gastric cancer by the use 
of MALDI-TOF/TOF mass spectrometer. A very recent 
comparative study was performed on gastric cancer 
(MKN45cell line) before and after exposing to 
Lavender aqueous extract. The results indicate that, 
among 1000 spots, more than 700 spots are imposed 
alternations in their expression levels. Of these proteins, 
expression of three cancer biomarkers, Annexin1, 
Anolase1 and HSP70 were suppressed by the extract 
[92]. 
8.5. Skin Cancer 
Skin cancer is skin growth with differing causes and 
varying degrees of malignancy. It is a common disease 
in all European-derived populations and has shown 
rapid increases in incidence over the last century. Basal 
cell carcinoma is one of the most common types of 
non-melanoma skin cancers in human [93-95]. 
Investigations indicate that function of specific genes in 
skin cancer alters. These alterations affect conserved 
regulators of cellular proliferation and viability, 
including the Sonic Hedgehog, Ras/Raf, ARF/p53, 
p16INK4A/CDK4/Rb and NF-B pathways. New 
modalities designed to target these specific proteins 
may represent promising approaches to therapy of 
human skin cancers [96]. As one of these methods is 
proteomics, a wide variety of proteins profiles has been 
extensively constructed via this technology. However, 
the comprehensive proteomic profiling of the skin, is 
still far from complete.  One of the first proteomics 
studies in skin cancer field was in 2000 [96]. This study 
compares the human epidermal stem cells with their 
differentiated daughters (transit amplifying cells).  In 
2003, in one study, six molecular chaperones, including 
HSP27, HSP60, HSP70, HSP84, ER60, and GRP78, 
were determined within the proteome map of the 
BALB/c abdominal, which belongs to the heat shock 
protein 90 family, was formerly identified as a 
tumor-specific transplantation antigen [97]. In another 
study, proteomics analysis was shown that, among 87 
proteins 76 of them were determined with drastic difference in 
expression which seventh were identified by databases [98]. 
In the other study, anticancer effects of arbutin 
investigated on the protein expression profile of A375 
  
 
Ivy Union Publishing | http: //www.ivyunion.org August 13, Volume 2 | Issue 2  
Zamanian-Azodi M et al. American Journals of Cancer Science 2013, 2:116-133 Page 12 of 18 
cell line. MALDI-Q-TOF MS and MS/MS identified 26 
differentially expressed proteins (7 up-regulated and 19 
down-regulated proteins) after treatment with arbutin,. 
Of these proteins, there were 13 isoforms of six 
identical proteins. Moreover, revealed that interaction 
network of 14 differentially expressed proteins 
correlated with the downstream regulation of p53 tumor 
suppressor and cell apoptosis. In addition, three 
up-regulated proteins (14-3-3G, VDAC-1 and p53) and 
five down-regulated proteins (ENPL, ENOA, IMDH2, 
PRDX1 and VIME) in arbutin-treated A375 cells were 
validated by RT-PCR analysis. These proteins were 
found to play significant roles in the suppression of 
cancer growth [99]. 
8.6. Prostate Cancer 
Prostate cancer rate is very high across the world; it is 
accounted for second male cancer deaths in the United 
States [100]. The need for other means of screening for 
this malignancy is prominent, due to shortcoming of the 
prostate-specific test for the early detection of prostate 
cancer antigen (PSA) [101]. One common treatment is 
androgen-deprivation therapy, which reduces symptoms 
in most patients. On the other hand, over time, patients 
develop tumors that are androgen-independent and 
finally fatal. First proteomics studies were around 2000 
when David K. Ornstein et al. worked on analysis of laser 
capture microdissected (LCM) human prostate cancer 
and in vitro prostate cell lines.  In this study normal 
and malignant epithelium from prostatectomy tissue 
specimens provided by LCM and the proteins analyzed 
by 2-D PAGE. Several proteins showed different 
expression including the well-known prostate biomarker, 
prostate-specific antigen (PSA), and intriguingly the 
remaining protein candidates were found to be at least as 
abundant as the PSA protein. The findings indicated that 
2-D PAGE analysis of LCM-derived cells can 
introduces considerable alterations in protein expression 
associated with prostate cancer. Identification of these 
proteins provides new possibility for introducing novel 
biomarkers related to prostate cancer. These biomarkers 
can be used as diagnostic probes or therapeutic targets 
[102]. Two years later, proteomics pattern in serum was 
used as indicator to identify prostate cancer. A suitable 
pattern constructed by MS spectra with a bioinformatics 
tool for detection of prostate cancer.  The proteomic 
pattern correctly predicted 36 (95%, 95% confidence 
interval [CI] = 82% to 99%) of 38 patients with prostate 
cancer, while 177 (78%, 95% CI = 72% to 83%) of 228 
patients were correctly classified as having benign 
conditions. For men with marginally elevated PSA 
levels (4–10 ng/mL; n = 137), the specificity was 71%. 
If validated in future series, serum proteomic pattern 
diagnostics may be of value in deciding whether to 
perform a biopsy on a man with an elevated PSA level 
[103]. 
In 2005, Brian L. Hood et al. published a paper in 
which they studied about proteomics pattern of 
paraffin-embedded prostate cancer tissue. Mass spectral 
analysis of prostate cancer (PCa) and benign prostate 
hyperplasia (BPH) led to identification of more 
biomarkers as like prostatic acid phosphatase, and 
macrophage inhibitory cytokine-1 [104]. According to 
some recent proteomics studies, more proteins become 
up-regulated and or down-regulated in prostate cancer. 
ACAT1, BDH1, HMGCL, and OXCT1 are proteins that 
their expression is increased in the In Vitro studies 
[105]. Another study implies on the role of 
diethylstilbestrol (DES) action in prostate cancer 
inhibition and its proteins alteration. The 2D-DIGE 
analyses revealed DES-induced expression changes for 
14 proteins (>1.3 fold; P<0.05) [106].  
8.7. Renal Cancer 
Renal cancer is the most deadly of urological 
malignancies. Molecular bases of this 
treatment-resistant neoplasm has been studied widely 
recently [107]. The first evaluation of renal carcinoma 
cancer (RCC) proteome was a comparison between 
normal renal and cancer type in 1997 in which 2-D 
PAGE was applied to determine normal and tumor 
kidney tissues in ten patients suffering from RCC.  
Among 2789 separated polypeptides, 43 of them were 
found through gel comparison, amino acid 
analysis, N-terminal sequencing, and/or 
immunodetection. Protein expression among normal 
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and tumor kidney tissues proved four polypeptides not 
present in RCC. One of them was identified as 
ubiquinol cytochrome c reductase (UQCR) and the 
second was mitochondrial NADH-ubiquinone oxido 
reductase complex I. Since the last biomarker 
determines role of mitochondrial  abnormality in RCC 
it helps to candidate mitochondria as a drug target in 
RCC [108]. In one study in 2004, heat shock protein 27 
over-expression was identified as a potential biomarker 
by 2-D PAGE separation, mass spectrometry, and 
Western blotting immunodetection methods. The result 
was also validated by immunohistochemistry on tissue 
sections [109]. 
Base on one recent proteomic study, expression 
levels of profilin-1 (Pfn1), 14–3-3 zeta/delta (14–3-3ζ), 
and galectin-1 (Gal-1) changed in RCC patients.  In 
clustering analysis of changed expression proteins 
showed that protein expression profile for metastatic 
RCC in aggressive and non-aggressive RCC is different 
[110]. Another study investigated on validates 
diagnostic and prognostic serum markers using 
proteomic profiling which several peptides were 
identified as having independent prognostic but not 
diagnostic significance on multivariable analysis [111].. 
It seems that biomarker discovery and proteomic 
pattern have a key role in diagnostic and therapeutic 
aspects of RCC. 
9. Conclusions 
On the whole, each of the approaches in cancer study 
has its own strengths and weaknesses, especially with 
regard to the sensitivity and specificity of that 
method. Proteomics is not an exception; as 
disadvantages, it still suffers from several drawbacks; 
some of these pitfalls include the lack of the detection 
of low abundance proteins such as receptor, regulatory, 
and signal transduction proteins. In addition, basic 
proteins as well as the membrane proteins that represent 
40% of all cellular proteins are hard to separate by 
proteomic methods. Some of these drawbacks can be 
solved by matching several techniques such as varieties 
of chromatography and electrophoresis in the 
multidimensional mode [12, 13]. However, proteomics 
is still the first choice technique to investigate major 
molecules relating to diseases such as cancer. What is 
expected from this sophisticated technology is that, not 
only detecting novel biomarkers and mapping 
biomarker panels related to the disease, but also by the 
aid of complicated bioinformatics make it as a 
outstanding high-throughput technique to determine 
molecular pathways and their interactions [25]. 
Therefore, it seems that, with aid of this marvelous 
achievement accompanied with other appropriate 
methods, approaching to cancer diagnosis and treatment 
may be accessible in the near future. 
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